Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, Kara Johnson, Gopal Sapparapu, John K Thomas, Guang Fan, Bill H Chang, Karina Thiel-Klare, Christopher A Eide, Craig Okada, Mike Palazzolo, Evan Lind, Yoko Kosaka, Brian J Druker, Nicholas Lydon, Peter M Bowers
PURPOSE: Targeted therapeutics are a goal of medicine. Methods for targeting T-cell lymphoma lack specificity for the malignant cell, leading to elimination of healthy cells. The T-cell receptor (TCR) is designed for antigen recognition. T-cell malignancies expand from a single clone which expresses one of 48 TCR variable beta (Vβ) genes, providing a distinct therapeutic target. We hypothesized that a monoclonal antibody that is exclusive to a specific Vβ would eliminate the malignant clone while having minimal effects on healthy T-cells...
May 18, 2023: Clinical Cancer Research